Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

Objectives. TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and atazanavir/ritonavir and safety and efficacy in treatment-experienced, HIV-1-infected patients. Methods. After a two-week lead-in of two nucleosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Orrell, Catherine, Felizarta, Franco, Nell, André, Kakuda, Thomas N., Lavreys, Ludo, Nijs, Steven, Tambuyzer, Lotke, Van Solingen-Ristea, Rodica, Tomaka, Frank L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312629/
https://www.ncbi.nlm.nih.gov/pubmed/25664185
http://dx.doi.org/10.1155/2015/938628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312629/
https://www.ncbi.nlm.nih.gov/pubmed/25664185
http://dx.doi.org/10.1155/2015/938628

Ejemplares similares